Rapastinel

Summary

Rapastinel (CHEMBL3544917) is a phase-3 clinical-stage protein; indicated across 2 conditions including major depressive disorder and obsessive-compulsive disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 2 conditions
• Clinical trials: 17
• Chemistry: 413.5 Da · C18H31N5O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3544917
Name	Rapastinel
Type	Protein
Max phase	3
FDA approved	no
PubChem CID	14539800
Molecular formula	C18H31N5O6
Molecular weight	413.5
InChIKey	GIBQQARAXHVEGD-BSOLPCOYSA-N

SMILES: C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N)N)O

IUPAC name: (2S)-1-[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]pyrrolidine-2-carboxamide

Also known as: GLYX-13, Rapastinel, Rapastinelum, Tppt-amide, RAPASTINEL, RAPASTINEL TRIFLUOROACETATE, Rapastinel Trifluoroacetate

Patent coverage: 157 distinct patent families (354 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
major depressive disorder	3	MONDO:0002009	MONDO:0002009
obsessive-compulsive disorder	2	MONDO:0008114	EFO:0004242

Clinical trials

Total trials: 17.

Phase distribution

Phase	Trials
PHASE3	10
PHASE2	4
PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02932943	PHASE3	COMPLETED	A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
NCT02943564	PHASE3	COMPLETED	A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)
NCT02943577	PHASE3	COMPLETED	A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)
NCT02951988	PHASE3	COMPLETED	A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder
NCT03002077	PHASE3	COMPLETED	Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder
NCT03560518	PHASE3	TERMINATED	Study of Rapastinel as Monotherapy in Patients With MDD
NCT03614156	PHASE3	TERMINATED	Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)
NCT03668600	PHASE3	TERMINATED	Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
NCT03675776	PHASE3	TERMINATED	Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)
NCT03855865	PHASE3	WITHDRAWN	Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)
NCT01234558	PHASE2	COMPLETED	Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
NCT01684163	PHASE2	COMPLETED	Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
NCT01844726	PHASE2	TERMINATED	Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness
NCT03352453	PHASE2	TERMINATED	A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder
NCT01014650	PHASE1	COMPLETED	Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers
NCT03799900	PHASE1	COMPLETED	Assessment of Abuse Potential of Rapastinel in Humans
NCT03814733	PHASE1	COMPLETED	Assessment of Effect of Rapastinel on Driving Performance

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).